Approach for Advanced Cancer Patients with Bone Metastases by the Bone Metastasis Board: A Single-institution Retrospective Study

Masahiro Kawahira; Fumihiko Nakamura; Hirofumi Shimada; Mariko Nishi; Takahiro Iwatsubo; Takako Shiomitsu; Hiroshi Maeda; Ayaka Osako; Kunihiro Miyazaki; Yusuke Kusumi; Akitoshi Murata; Hiroko Osako; Takeshi Hori

Return

Approach for Advanced Cancer Patients with Bone Metastases by the Bone Metastasis Board: A Single-institution Retrospective Study

VernacularTitle:単一施設における骨転移チームによる介入の後方視的検討—がん診療連携拠点病院における骨転移カンファレンスの現状—
Author: Masahiro KAWAHIRA ¹ ; Fumihiko NAKAMURA ² ; Hirofumi SHIMADA ³ ; Mariko NISHI ¹ ; Takahiro IWATSUBO ¹ ; Takako SHIOMITSU ¹ ; Hiroshi MAEDA ⁴ ; Ayaka OSAKO ⁴ ; Kunihiro MIYAZAKI ⁵ ; Yusuke KUSUMI ⁵ ; Akitoshi MURATA ⁵ ; Hiroko OSAKO ¹ ; Takeshi HORI ¹
Author Information

1. Department of Medical Oncology, Palliative Care Center, Kagoshima City Hospital
2. Department of Radiation Oncology, Kagoshima City Hospital
3. Department of Orthopaedic Surgery, Kagoshima City Hospital
4. Department of Pharmacy, Kagoshima City Hospital
5. Department of Physical Therapy, Kagoshima City Hospital
Keywords: bone metastasis board (BMB); cancer board; skeletal related event (SRE)
From:Palliative Care Research 2023;18(1):61-66
CountryJapan
Language:Japanese
Abstract: Prevention, early diagnosis, and early treatment of skeletal-related events (SREs) are important in the treatment of potential or current cases of bone metastasis. In August 2020, our hospital established the bone metastasis team and the bone metastasis board (BMB) started actively engaging in activities aimed at improving the outcome of bone metastasis. We retrospectively examined whether a combined modality therapy started in the diagnosis of bone metastases could prevent the onset of SREs and whether it could prolong survival and improve activities of daily living. The 75 advanced cancer patients who underwent BMB at our hospital from August 1, 2020 to July 31, 2022 were divided into two groups according to when BMB performed before and after SREs for comparative analysis. Numerical Rating Scale improved, however Performance Status did not improve in both groups, and there was no difference in survival between the both groups (15.3 vs. 9.0 months, HR: 0.74, 95%; CI: 0.42–1.29, p=0.29). In conclusion, patients who suffered from SREs from the time of bone metastasis diagnosis were treated early. However, the incidence of SREs after BMB in our hospital was 22.6%, and it is necessary to actively work to prevent SREs in the future.